N S Abramson, S F Kelsey, P Safar, K Sutton-Tyrrell
Index: Ann. Emerg. Med. 21(12) , 1480-2, (1992)
Full Text: HTML
Expensive clinical trials have become the gold standard for evaluating the efficacy of promising new therapeutic agents. Full exploration of the collected data is routine to maximize the yield of the information available. However, potential methodologic flaws in these extensive analyses may not be appreciated by investigators or readers. One such problem with subgroup analyses is discussed, using hypothetical examples and data from a recently completed clinical trial of brain resuscitation as illustrations.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Lidoflazine
CAS:3416-26-0 |
C30H35F2N3O |
|
Protective effects of the lazaroid U74500A and lidoflazine o...
1993-01-01 [Transpl. Int. 6(5) , 281-4, (1993)] |
|
1,4-Dihydropyridines bearing a pharmacophoric fragment of li...
1996-10-01 [Bioorg. Med. Chem. 4(10) , 1629-35, (1996)] |
|
Effects of lidoflazine on left ventricular function in patie...
1997-02-01 [J. Cardiothorac. Vasc. Anesth. 11(1) , 42-8, (1997)] |
|
The pathophysiology of angina pectoris and the effect of lid...
1982-01-01 [Circulation 65(1 Pt 2) , I27-32, (1982)] |
|
Lidoflazine and myocardial protection.
1995-05-01 [J. Thorac. Cardiovasc. Surg. 109(5) , 1013-4; discussion 1015, (1995)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
